Multiple sclerosis: Improve monitoring, inform treatment decisions
Research into multiple sclerosis (MS) is no exception. Ten leading clinical centers, the biotechnology company Biogen, and Siemens Healthineers have joined forces to help combat this disease of the central nervous system.
Digging into real-world data
The role of imaging
MS on MRI images
Precision diagnostics, precision treatment
-  Ø Torkildsen, K-M Myhr, and L Bø: Disease-modifying treatments for multiple sclerosis – a review of approved medications. Eur J Neurol. 2016 Jan; 23(Suppl 1): 18–27. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670697/
1 The product/feature is still under development and not commercially available yet. Its future availability cannot be ensured.
The concepts and information presented in this paper are based on research and are not commercially available. The statements by Siemens Healthineers customers described herein are based on results that were achieved in the customer’s unique setting. Since there is no “typical” hospital and many variables exist (e.g., hospital size, case mix, level of IT adoption) there can be no guarantee that other customers will achieve the same results.